Biote (BTMD) Cash & Equivalents (2020 - 2026)

Biote's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $5.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 87.24% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $5.3 million (down 87.24% YoY), while the FY2025 annual figure was $24.1 million, down 38.68% from the prior year.
• Cash & Equivalents was $5.3 million for Q1 2026 at Biote, down from $24.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $89.0 million in Q4 2023 to a low of $5.3 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $51.7 million across 5 years, with a median of $41.7 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents surged 265.57% in 2022, then sank 87.24% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $79.2 million in 2022, then rose by 12.33% to $89.0 million in 2023, then sank by 55.8% to $39.3 million in 2024, then plunged by 38.68% to $24.1 million in 2025, then slumped by 77.95% to $5.3 million in 2026.
• The last three Cash & Equivalents figures came in at $5.3 million (Q1 2026), $24.1 million (Q4 2025), and $28.0 million (Q3 2025), per Business Quant data.